PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩70 per share · Prices as of the 2026-10-02 close
Sewoon Medical continues to post revenue growth on the back of expanding domestic market share for its core medical suction devices, though net income attributable to owners has softened slightly in recent quarters.
2025 consolidated revenue reached KRW 63.7 billion and operating profit KRW 12.7 billion, both up year-on-year, while net income attributable to owners declined slightly.
Net income attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) totaled approximately KRW 13.9 billion.
The company's core medical suction device is gaining domestic market share on the strength of faster wound healing and reduced antibiotic use.
Production bases in Cheonan and Vietnam support price competitiveness, while the company is expanding European exports of its blood and fluid warmers.
The debt ratio remains in the single digits, and operating cash flow has exceeded operating profit, reflecting a stable financial structure.
Sewoon Medical is a KOSDAQ-listed medical device specialist that manufactures, imports, and sells consumable medical devices such as medical suction devices and urinary catheters.
Founded in 1969 and listed on KOSDAQ in 2008, the company built its export foundation by obtaining CE certification in 1997 and FDA approval in 2002. It supplies general hospitals through a nationwide distributor network and maintains a leading domestic position among peers in its device category.
Its core medical suction device continues to gain domestic market share on the back of faster wound healing and reduced antibiotic use.
The company is also expanding European exports of its blood and fluid warmers through quality improvements, while diversifying into vascular access device development to pursue global market entry.
Production is split between a plant in Cheonan, South Chungcheong Province, and a Vietnam facility operating in a mass-production system, supporting price competitiveness while meeting both domestic and overseas demand.
The competitive landscape centers on rivalry with domestic small and mid-sized consumable medical device makers, while some product lines overlap with larger global medical device companies abroad.
Given this structure, a significant portion of revenue still relies on domestic hospital demand, even as growing export exposure built on overseas certifications is emerging as a mid- to long-term growth pillar.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩15.7B | ₩2.4B | 15.6% |
| 2025Q3 | ₩16.8B | ₩3.8B | 22.3% |
| 2025Q4 | ₩16.6B | ₩3.7B | 22.6% |
| 2026Q1 | ₩15.4B | ₩3.4B | 22.0% |
| 2026Q2 | ₩17.7B | ₩3.4B | 19.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩60.1B | ₩12.2B | ₩10.4B | 20.3% | 8.5% | 6.0% |
| 2023 | ₩68.2B | ₩16.9B | ₩15B | 24.8% | 11.1% | 6.5% |
| 2024 | ₩60.2B | ₩11.4B | ₩12.2B | 18.9% | 8.3% | 5.2% |
| 2025 | ₩63.7B | ₩12.7B | ₩11.9B | 20.0% | 7.9% | 6.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated revenue rose to KRW 63.66 billion in 2025 from KRW 60.15 billion in 2024, while operating profit increased to KRW 12.70 billion from KRW 11.38 billion, lifting the operating margin from 18.9% to 20.0%.
Net income attributable to owners, however, edged down to KRW 11.91 billion from KRW 12.16 billion in 2024, still solid compared with KRW 14.96 billion in 2023 and KRW 10.41 billion in 2022, but showing that profit recovery has not kept pace with the improvement in revenue and operating profit.
On a quarterly basis, results were strong in the third quarter of 2025 (revenue KRW 16.83 billion, operating profit KRW 3.76 billion, net income to owners KRW 3.70 billion) and remained elevated through the fourth quarter (revenue KRW 16.59 billion, operating profit KRW 3.75 billion, net income KRW 3.54 billion).
In the first quarter of 2026 (revenue KRW 15.39 billion, operating profit KRW 3.38 billion, net income KRW 3.43 billion) and second quarter (revenue KRW 17.71 billion, operating profit KRW 3.44 billion, net income KRW 3.23 billion), however, revenue rose again while operating profit and net income flattened or edged lower quarter-on-quarter.
Net income attributable to owners over the most recent four quarters (Q3 2025 through Q2 2026) totaled approximately KRW 13.90 billion, indicating that the annualized profit level has held broadly steady.
The operating margin declined from a high of 24.8% in 2023 to 18.9% in 2024 before partially recovering to 20.0% in 2025.
On financial stability, the debt ratio stayed in the single digits, in a 5-7% range from 2022 through 2025, and 2025 operating cash flow of KRW 17.77 billion exceeded that year's operating profit of KRW 12.70 billion, suggesting cash generation was stronger than accounting profit.
The domestic medical device market in Korea is estimated at KRW 11.877 trillion as of 2025, with an average annual growth rate of about 7.25%. Market size expanded from KRW 7.8039 trillion in 2019 to KRW 11.8782 trillion in 2022, saw some stagnation in 2023-2024, and resumed growth in 2025.
Sewoon Medical's core product lines, medical suction devices and catheters, belong to a consumable device category that benefits from structural demand drivers such as an aging population, rising chronic disease prevalence, and stricter infection control practices.
The global medical devices market is likewise in a gradual expansion phase, estimated at $572.31 billion in 2025 and projected to grow to $604.99 billion in 2026.
That said, the global catheter and suction device sub-markets include large multinational players such as Boston Scientific, Medtronic, and Stryker, making competitive intensity relatively high overseas.
In Europe, tightening conformity assessment and post-market surveillance requirements under the Medical Device Regulation (MDR) are adding to compliance costs, a structural shift that weighs more heavily on smaller manufacturers.
Against this backdrop, Sewoon Medical appears to be pursuing a dual strategy of defending its leading domestic market share while expanding exports of select products, leveraging overseas certifications, particularly toward Europe.
The company is pursuing expanded European exports of its blood and fluid warmers through quality improvements, a move that can be read as a gradual attempt to increase the overseas share of a historically domestic-centered revenue base.
It is also reportedly diversifying through development of a new vascular access device, which, if commercialized, could add a new revenue stream alongside the existing suction device and catheter-centered portfolio.
On the production side, the company maintains a policy of leveraging mass-production systems at its Cheonan and Vietnam plants to secure price competitiveness and respond to both domestic and overseas demand growth.
However, no specific order volumes, capacity expansion plans, or quantitative timing guidance for revenue contribution were identified in available sources, so the pace of these initiatives and when they will show up in reported revenue will need to be confirmed through future disclosures.
Given that recent quarters have shown revenue growth alongside flat or slightly declining operating profit and net income, the timing at which new initiatives begin contributing to margin improvement will be a key point to watch.
Overall, the company's growth narrative centers on two pillars, defending domestic market share and diversifying overseas exports, and how quickly these translate into reported results is the item to monitor going forward.
The current share price trades at a price-to-book ratio below 1, indicating the market is applying a discount relative to net asset value.
The earnings-based multiple appears to sit within the range of the stock's multi-year trading band, and the recent flattening in quarterly profit may be partly reflected in how that multiple has formed.
On the dividend side, the company has maintained a track record of cash dividends, though the yield level appears to sit on the lower end relative to sector peers.
Given that annual earnings peaked in 2023, softened, and then recovered in revenue and operating profit through 2024-2025, whether that profit trajectory reasserts itself going forward is a relevant consideration for valuation.
A low debt ratio and stable operating cash flow are factors that could be viewed favorably from a financial risk standpoint.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The company's flagship medical suction device continues to gain domestic market share on the strength of faster wound healing and reduced antibiotic use. This has served as a core driver of revenue growth, underpinning the year-on-year increase in 2025 annual revenue. A nationwide distributor network supplying general hospitals provides a stable demand base.
The debt ratio has stayed in the single digits throughout 2022-2025, leaving substantial financial flexibility. 2025 operating cash flow of KRW 17.77 billion exceeded that year's operating profit of KRW 12.70 billion, indicating cash generation stronger than accounting profit. This financial stability could support capacity for new investment or continued dividends.
The company is pursuing expanded European exports of its blood and fluid warmers through quality improvements, while seeking portfolio diversification via development of a new vascular access device.
Existing overseas certifications, including CE marking obtained in 1997 and FDA approval in 2002, could serve as a springboard for expanding new export categories. An increase in overseas revenue share relative to the historically domestic-centered structure could diversify the company's growth drivers.
In the first and second quarters of 2026, revenue rose again but operating profit and net income attributable to owners flattened or edged slightly lower quarter-on-quarter.
Full-year 2025 net income to owners also declined slightly year-on-year, continuing a pattern in which profit growth has lagged behind revenue and operating profit improvement. Whether this pattern persists will need to be confirmed in coming quarterly results.
The operating margin has shown significant year-to-year volatility, falling from 24.8% in 2023 to 18.9% in 2024 before only partially recovering to 20.0% in 2025. This suggests the business is sensitive to cost pressures or product mix shifts. Whether margin direction improves steadily will require further confirmation in future results.
Overseas catheter and suction device markets include a number of large multinational players such as Boston Scientific, Medtronic, and Stryker, making competitive intensity relatively high.
In Europe, tightening conformity assessment and post-market surveillance requirements under the Medical Device Regulation could increase compliance costs for smaller manufacturers. This environment could affect the pace or cost of the company's planned export expansion.
Recent quarters have shown a divergent pattern of rising revenue alongside stagnant operating profit and net income. Annual operating margins have also swung widely between 18.9% and 24.8%, making it difficult to simply extrapolate any single quarter's or year's profit level. Continued monitoring of upcoming quarterly disclosures will be needed to assess whether recent trends persist.
The strategy of expanding European exports presupposes meeting increasingly stringent overseas regulatory requirements such as the Medical Device Regulation.
Smaller manufacturers may face relatively higher burdens from technical documentation and post-market surveillance costs, and any setback in obtaining or maintaining certification could affect export plans. Progress on relevant certifications will need to be confirmed through future disclosures or IR materials.
Operating a production base in Vietnam and expanding overseas export exposure can increase sensitivity to foreign exchange fluctuations.
Changes in raw material prices needed for consumable medical device manufacturing could also affect the cost structure, potentially adding pressure on profitability in conjunction with year-to-year operating margin volatility.
Specific hedging policies or raw material sourcing structures were not confirmed in available sources and would require further verification.
Check whether the operating profit and net income stagnation seen in the two most recent quarters continues in the cumulative third-quarter results.
Monitor for any disclosures of new contracts or certifications related to the expansion of blood and fluid warmer exports to Europe.
Check whether the new vascular access device begins contributing to revenue and observe any changes in utilization rates at the Vietnam and Cheonan plants.
Check the confirmed 2026 full-year results and dividend resolution to assess whether profit recovery continues and whether dividend policy changes.
Sewoon Medical has continued to grow revenue by expanding its domestic market share centered on medical suction devices, and 2025 saw both revenue and operating profit improve year-on-year.
However, net income attributable to owners edged down slightly in 2025, and operating profit and net income remained flat relative to revenue growth in the first two quarters of 2026, leaving the question of qualitative earnings improvement still to be resolved.
The financial structure remains solid, underpinned by a low debt ratio and stable operating cash flow, which could provide capacity for new business investment or continued dividends.
European export expansion and development of a new vascular access device could form pillars of a longer-term growth story, but quantitative information on the specific timing and scale of revenue contribution remains limited.
On valuation, the share price appears to trade at a discount to net asset value, while the earnings multiple sits within the stock's historical trading band.
Overall, the company presents a mix of bullish factors (market share gains, financial stability, export diversification efforts) and bearish factors (recent profit stagnation, margin volatility, overseas competitive and regulatory pressures), making continued monitoring of upcoming quarterly results and new business progress important.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.